Analysis of pathogen distribution and drug resistance in patients with lung cancer complicating non-fermentative bacteria lung infection / 国际检验医学杂志

ABSTRACT

Objective To analyze the pathogen distribution and drug‐resistance characteristics in the patients with lung cancer complicating non‐fermentative bacteria lung infection to provide the basis for clinicians to prevent infection and rationally use anti‐bacterial drugs .Methods The clinically submitted respiratory tract specimens in the patients with lung cancer in our hospital from January 2009 to July 2015 were retrospectively analyzed .The isolated pathogenic bacteria were identified by adopting the France Bio‐plum‐Egyptian company Vitek2‐Compact identification instrument ,the drug sensitivity test was conducted by using the K‐B disk diffusion method .The statistical analysis of data was performed by adopting the WHONET 5 .6 software .Results 176 strains of non‐fermentative bacteria mainly came from sputum ,accounting for 80 .1% ,the detection rate of Pseudomonas aeruginosa was highest ,accounting for 48 .2% ,followed by Acinetobacter baumannii and Stenotrophomonas maltophilia ,accounting for 32 .4% and 16 .5% respectively ;the drug susceptibility test results showed that non‐fermentative bacteria had different degrees of resistance to antibacterial drugs or even multiple drug resistance ,in which the resistance of Pseudomonas aeruginosa to amikacin ,tobramycin and cefoperazone/sulbactam ,the resistance of Acinetobacter baumannii to amikacin ,cefoperazone/sulbactam and the resistance of Stenotrophomonas maltophilia to minocycline ,cotrimoxazole and cefoperazone/sulbactam were less than 30 .0% ,which to other an‐tibacterial drugs were more than 30 .0% .Conclusion Non‐fermentative bacteria are common pathogenic bacteria in hospital infec‐tion ,non‐fermentative bacteria isolated from the patients with lung cancer complicating pulmonary infection have serious resistance to commonly used antibacterial drugs ,therefore clinic should strengthen the monitoring of pathogenic bacteria and drug resistance . Cefoperazone/sulbactam is the first choice for treating these bacterial infections .